Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
Syntara LimitedTelephone
61.2.9454.7200
Address
Frenchs Forest 20 Rodborough Road Sydney, New South Wales (NSW) 2086
Description
Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. Its respiratory products include bronchitol and aridol. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.08
Trade Value (12mth)
AU$25,862.00
1 week
-6.06%
1 month
37.78%
YTD
226.32%
1 year
158.33%
All time high
4.31
EPS 3 yr Growth
200.00%
EBITDA Margin
N/A
Operating Cashflow
-$14m
Free Cash Flow Return
-202.20%
ROIC
-190.80%
Interest Coverage
-47.80
Quick Ratio
1.80
Shares on Issue (Fully Dilluted)
1092m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.03
Date | Announcements |
---|---|
19 December 24 |
Application for quotation of securities - SNT
×
Application for quotation of securities - SNT |
19 December 24 |
Section 708A(5)(e) notice
×
Section 708A(5)(e) notice |
12 December 24 |
Placement
×
Placement |
12 December 24 |
Equity Raising Presentation
×
Equity Raising Presentation |
12 December 24 |
Proposed issue of securities - SNT
×
Proposed issue of securities - SNT |
12 December 24 |
Proposed issue of securities - SNT
×
Proposed issue of securities - SNT |
10 December 24 |
Trading Halt
×
Trading Halt |
10 December 24 |
Notice of SNT-5505 Interim Phase 2 data webinar
×
Notice of SNT-5505 Interim Phase 2 data webinar |
10 December 24 |
Interim data in Phase 2 study of SNT-5505 in myelofibrosis
×
Interim data in Phase 2 study of SNT-5505 in myelofibrosis |
10 December 24 |
Presentation: Phase 2 study of SNT-5505 in myelofibrosis
×
Presentation: Phase 2 study of SNT-5505 in myelofibrosis |
04 December 24 |
Change in substantial holding
×
Change in substantial holding |
04 December 24 |
Pause in Trading
×
Pause in Trading |
04 December 24 |
Response to ASX Price Query
×
Response to ASX Price Query |
29 November 24 |
Notification regarding unquoted securities - SNT
×
Notification regarding unquoted securities - SNT |
29 November 24 |
Change of Director's Interest Notice - GP
×
Change of Director's Interest Notice - GP |
28 November 24 |
Chair's Address to Shareholders
×
Chair's Address to Shareholders |
28 November 24 |
CEO AGM Presentation to Shareholders
×
CEO AGM Presentation to Shareholders |
28 November 24 |
Results of Meeting
×
Results of Meeting |
06 November 24 |
Selected for oral presentation at ASH
×
Selected for oral presentation at ASH |
30 October 24 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
30 October 24 |
Quarterly Activities Report
×
Quarterly Activities Report |
30 October 24 |
Presentation for September Quarterly Shareholder Update
×
Presentation for September Quarterly Shareholder Update |
29 October 24 |
Appendix 4C quarterly webinar
×
Appendix 4C quarterly webinar |
28 October 24 |
Receipt of R&D Tax Incentive
×
Receipt of R&D Tax Incentive |
25 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.